1. Signaling Pathways
  2. Immunology/Inflammation
  3. CD20


CD20 is a 33-37 kDa non-glycosylated protein expressed specifically on the surface of normal and malignant B lymphocytes, and belongs to the MS4A (membrane-spanning 4-domain family A) protein family. CD20 is a general B-cell marker expressed by the majority of B cells starting from late pre-B lymphocytes (it is not expressed by pro-B lymphocytes), and its expression is lost in terminally differentiated plasmablasts and plasma cells. Early experiments suggested that it was important in the regulation of human B-cell activation, proliferation, and Ca2+ transport. However, CD20-deficient mice appeared normal. Hence, the exact biological function of CD20 and its physiological ligand remain to be fully defined.240 Regardless of the uncertainty in the biological role of this antigen, it is a good target for cancer immunotherapy.

CD20 相关产品 (8):

目录号 产品名 作用方式 纯度
  • HY-P9910


    Obinutuzumab (GA101) 是新型糖工程化 II 型 CD20 人源化 IgG1 单克隆抗体,用于非霍奇金淋巴瘤的研究。
  • HY-P99326
    Tositumomab Inhibitor
    Tositumomab是一种靶向CD20抗原的小鼠IgG2a lambda单克隆抗体,CD20抗原存在于正常和恶性B淋巴细胞表面。
  • HY-P99538


    Ublituximab (LFB-R603; TG-1101; TGTX-1101) 是靶向 CD20 抗原上独特表位的下一代 1 型嵌合单克隆抗体。Ublituximab 具有抗癌作用。
  • HY-P9946
    Ibritumomab tiuxetan Inhibitor
    Ibritumomab tiuxetan 是一种免疫偶联物,由与螯合剂 Tiuxetan 共价结合的鼠 IgG1κ 抗 CD20 单克隆抗体 Ibritumomab 组成。Ibritumomab tiuxetan 可以与放射性同位素结合,用于非霍奇金 B 细胞淋巴瘤的研究。
  • HY-P99855
    Divozilimab Inhibitor
    Divozilimab (BCD-132) 是一种抗 CD20 (CD20) 的人源化单克隆抗体。Divozilimab 可用于多发性硬化症研究。
  • HY-P99308
    Ocaratuzumab Inhibitor
    Ocaratuzumab (AME 133v),一种 Fc 工程抗体,是人源化的 IgG1 抗 CD20 单克隆抗体,Kd 值为 ~100 pM。Ocaratuzumab 表现出更有效的抗体依赖性细胞介导的细胞毒性 (ADCC)。
  • HY-P99501
    Zuberitamab Inhibitor
    Zuberitamab (HS006) 是一种靶向CD20 的单克隆抗体,可用于癌症,包括弥漫性大 B 细胞淋巴瘤研究。
  • HY-P99483
    Blontuvetmab Inhibitor
    Blontuvetmab (AT 004) 是一种犬源化 CD20 单克隆抗体。Blontuvetmab 可用于犬 B 细胞淋巴瘤的研究。